» Articles » PMID: 21241810

Immunotherapeutic Modulation of the Suppressive Liver and Tumor Microenvironments

Overview
Date 2011 Jan 19
PMID 21241810
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

The liver is an immunologically unique organ, consisting of resident hematopoietic and parenchymal cells which often contribute to a relatively tolerant microenvironment. It is also becoming increasingly clear that tumor-induced immunosuppression occurs via many of the same cellular mechanisms which contribute to the tolerogenic liver microenvironment. Myeloid cells, consisting of dendritic cells (DC), macrophages and myeloid derived suppressor cells (MDSC), have been implicated in providing a tolerogenic liver environment and immune dysfunction within the tumor microenvironment which can favor tumor progression. As we increase our understanding of the biological mechanisms involved for each phenotypic and/or functionally distinct leukocyte subset, immunotherapeutic strategies can be developed to overcome the inherent barriers to the development of improved strategies for the treatment of liver disease and tumors. In this review, we discuss the principal myeloid cell-based contributions to immunosuppression that are shared between the liver and tumor microenvironments. We further highlight immune-based strategies shown to modulate immunoregulatory cells within each microenvironment and enhance anti-tumor responses.

Citing Articles

Role and therapeutic potential of E3s in the tumor microenvironment of hepatocellular carcinoma.

Wang H, Li Q, Tang Q, Shi G, Wu G, Mao X Front Immunol. 2024; 15:1483721.

PMID: 39544935 PMC: 11560419. DOI: 10.3389/fimmu.2024.1483721.


Tumour-derived exosomes in liver metastasis: A Pandora's box.

Li S, Qu Y, Liu L, Wang C, Yuan L, Bai H Cell Prolif. 2023; 56(10):e13452.

PMID: 36941028 PMC: 10542622. DOI: 10.1111/cpr.13452.


Differential organ-specific tumor response to first-line immune checkpoint inhibitor therapy in non-small cell lung cancer-a retrospective cohort study.

Wang Q, Fang Y, Li C, Leong T, Provencio M, Oh I Transl Lung Cancer Res. 2023; 12(2):312-321.

PMID: 36895937 PMC: 9989803. DOI: 10.21037/tlcr-23-83.


Exploring the role of mast cells in the progression of liver disease.

Huang S, Wu H, Luo F, Zhang B, Li T, Yang Z Front Physiol. 2022; 13:964887.

PMID: 36176778 PMC: 9513450. DOI: 10.3389/fphys.2022.964887.


The presence and size of intrahepatic tumors determine the therapeutic efficacy of nivolumab in advanced hepatocellular carcinoma.

Kim H, Kim C, Hong J, Kim I, Kang B, Jung S Ther Adv Med Oncol. 2022; 14:17588359221113266.

PMID: 35860833 PMC: 9290164. DOI: 10.1177/17588359221113266.


References
1.
Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J . RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis. 2008; 29(10):2035-43. PMC: 2556970. DOI: 10.1093/carcin/bgn188. View

2.
Litzinger M, Fernando R, Curiel T, Grosenbach D, Schlom J, Palena C . IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood. 2007; 110(9):3192-201. PMC: 2200901. DOI: 10.1182/blood-2007-06-094615. View

3.
Nausch N, Galani I, Schlecker E, Cerwenka A . Mononuclear myeloid-derived "suppressor" cells express RAE-1 and activate natural killer cells. Blood. 2008; 112(10):4080-9. PMC: 2582006. DOI: 10.1182/blood-2008-03-143776. View

4.
Lian Z, Okada T, He X, Kita H, Liu Y, Ansari A . Heterogeneity of dendritic cells in the mouse liver: identification and characterization of four distinct populations. J Immunol. 2003; 170(5):2323-30. DOI: 10.4049/jimmunol.170.5.2323. View

5.
Dieu-Nosjean M, Antoine M, Danel C, Heudes D, Wislez M, Poulot V . Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol. 2008; 26(27):4410-7. DOI: 10.1200/JCO.2007.15.0284. View